Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan
Tokyo, Feb 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. announced today that it
will launch the vascular embolization device DC Bead(R) (specially controlled
medical device) in Japan on February 4.
DC Bead contains hydrophilic microspheres made from cross-linked polyvinyl
alcohol polymer. Developed by Biocompatibles UK Limited (Biocompatibles), a BTG
International group company, as an intravascular embolization device, it is
injected via catheter into targeted blood vessels to achieve selective
embolization. DC Bead is already marketed as an effective embolization device
in the treatment of hepatocellular carcinoma (HCC) and other hypervascularized
tumors in more than 50 countries and territories worldwide, including in Europe
and the United States.
Eisai acquired the exclusive rights to develop and market DC Bead in Japan
from Biocompatibles in July 2009 and received manufacturing and marketing
authorization for the device from Japan's Ministry of Health, Labour and
Welfare in April 2013 for use in transcatheter arterial embolization (TAE) in
patients with HCC. On February 1, 2014, DC Bead was classified in the Special
Treatment Materials (STM) category for medical device reimbursement under the
country's National Health Insurance system.
In Japan, the Eisai Group markets a diverse range of medical devices and
pharmaceuticals for the diagnosis and treatment of liver diseases. These
products include the non-ionic contrast medium Iomeron(R) and non-ionic
contrast medium for MRI ProHance(R), both of which are imaging devices used in
HCC diagnosis, the in-vitro diagnostic tool PIVKA-II Kit, which is used to
measure the HCC marker PIVKA-II/DCP, and two liver disease medications and
anti-allergy agents, Stronger Neo-Minophagen(R) C and Glycyron(R) Tablets.
Through the launch of DC Bead in Japan, Eisai seeks to further enhance its
liver disease product portfolio in the country as well as continue to
contribute to addressing the diverse needs of, and increasing the benefits
provided to, patients with HCC and their families.
About DC Bead
DC Bead contains hydrophilic microspheres (beads) produced made from
cross-linked polyvinyl alcohol polymer. As a vascular embolization device, it
is injected via catheter into targeted blood vessels to achieve selective
embolization. Due to the beads being both microscopic and uniformly spherical,
DC Bead allows for sustained embolization of targeted blood vessels based on
vascular diameter and tumor size, with each embolization procedure confirmed
through endoscopic observation of the targeted vessels. Following its launch in
Japan, the device will be domestically available in three bead sizes (100-300
micro-m, 300-500 micro-m, and 500-700 micro-m) so that an appropriate bead size
can be selected based on vascular diameter, tumor size and extent of intended
embolization in the targeted blood vessel.
In addition to DC Bead's indication in Japan for transcatheter arterial
embolization (TAE) therapy in patients with hepatocellular carcinoma (HCC),
Eisai is currently conducting Phase III clinical trials of DC Bead in Japan as
an effective embolization device for treating other hypervascularized tumors.
Hypervascularized tumors most commonly refer to hepatocellular carcinoma
(HCC), renal cell carcinoma, bone and soft tissue sarcoma, and other tumors
that receive nourishment via a sophisticated vascular network formed in tumor
About Transcatheter Arterial Embolization (TAE)
TAE is a therapy that selectively obstructs blood circulation to induce
necrosis in hepatocellular carcinoma (HCC) by injecting embolization material
into the hepatic artery, the artery that supplies nutrient blood to the tumor.
In contrast to healthy liver cells, which receive blood from both the hepatic
artery and portal vein, HCC cells receive blood mainly from the hepatic artery
via a vascular network formed in the tumor tissue.
Consequently, by using embolizing material to selectively embolize blood
vessels in the hepatic artery, selective necrosis can be more effectively
induced at the tumor site. There are two types of TAE therapy: one involving
embolization without chemotherapy, and transcatheter arterial
chemo-embolization (TACE), the latter of which is performed in combination with
chemotherapeutic agents to suppress cancer cell activity.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care
(hhc) company that discovers, develops and markets products throughout the
world. Eisai focuses its efforts in three therapeutic areas: integrative
neuroscience, including neurology and psychiatric medicines; integrative
oncology, which encompasses oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai actively
participates in all aspects of the worldwide healthcare system. For more
information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department,
Eisai Co., Ltd.
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
Provider ID: 00028618
Press spacebar to pause and continue. Press esc to stop.